ClinicalTrials.gg
CompletedNCT01027949FREEDOM-EXTUpdated May 10, 2021Results posted

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension

A Phase 3 interventional study of Oral Treprostinil in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed at 135 sites in 20 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-05-10.

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled Jan 2007, registered Dec 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
894
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
Largest of 44
894 · median 32
Started
2007
with 1 other
Phase 3
14 of 44
1 open now
Registered
13th of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one has the largest enrollment, is one of 2 that started in 2007, is one of 14 in phase 3, and was the 13th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This study provided/continued to provide oral treprostinil (UT-15C SR; treprostinil diethanolamine) to eligible subjects who participated in Studies TDE-PH-202, TDE-PH-203, TDE-PH-205, TDE-PH-301, TDE-PH-302, and TDE-PH-308. The study assessed the long term safety of oral treprostinil and the effect of continued treatment with oral treprostinil on exercise capacity after 1 year of treatment.

Read the detailed description

This was an international, multicenter, open-label study designed to provide oral treprostinil for eligible subjects who participated in Studies TDE-PH-301, TDE-PH-302, TDE-PH-308, TDE-PH-202, TDE PH 203, and TDE-PH-205. Subjects randomly allocated to receive oral treprostinil in Studies TDE-PH-301, TDE-PH-302, or TDE-PH-308 and enrolled in this open-label study completed visits at Months 6, 12, 24, 36, and yearly visits thereafter. Subjects randomly allocated to receive placebo in Studies TDE-PH-301, TDE-PH-302, or TDE-PH-308 completed visits at Months 3, 6, 12, 24, 36, and yearly visits thereafter. Subjects that transitioned from Studies TDE-PH-202, TDE-PH-203, and TDE-PH-205 (that had an open-label study design) followed the regimen for subjects receiving oral treprostinil. A 6-Minute Walk Test (6MWT) and Borg dyspnea score were conducted at the visit which occurred 12 months after the subject's first exposure to oral treprostinil.

Adverse events (AEs) were reported continuously throughout the study; any AEs ongoing at the time of discharge from Studies TDE PH-301, TDE PH-302, TDE-PH-308, TDE-PH-202, TDE-PH-203, and TDE-PH-205 were recorded as AEs and marked as "ongoing from previous study" in the subject's electronic Case Report Form (eCRF). Study drug dosing and pulmonary arterial hypertension (PAH) concomitant medication usage were assessed at each scheduled study visit and recorded in the subject's eCRF.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject remained on study drug and completed all assessments during the Treatment Phase of the previous study (TDE-PH-202, TDE-PH-203, TDE-PH-205, TDE-PH-301, TDE PH-302, or TDE-PH-308) OR the subject permanently discontinued study drug during the Treatment Phase of the previous study due to clinical worsening (as defined in the protocol of the previous study), completed premature termination assessments prior to discontinuing study drug, completed all remaining scheduled study visits, AND received placebo during the Treatment Phase of the previous studies OR the subject was randomized into Group 1 or Group 2 in Study TDE PH 202, permanently discontinued study drug during the 12-week Treatment Phase due to clinical worsening, completed all premature termination assessments prior to discontinuing study drug, and completed all remaining scheduled study visits and assessments (with the exception of the hemodynamic measurements) through Week 12. Such subjects should have started treatment with oral treprostinil in the open-label study at 0.25 mg twice daily (BID).
  2. The subject voluntarily gave to participate in the study.
  3. Women of includes any female who had experienced menarche and who had not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or was not (defined as amenorrhea for at least 12 consecutive months). Sexually active women of childbearing potential must have used 2 effective forms of during the length of the study. Medically acceptable forms of effective contraception included: (1) approved hormonal contraceptives (such as birth control pills), (2) barrier methods (such as a condom or diaphragm) used with a spermicide, (3) an intrauterine device, (4) partner vasectomy, or (5) abstinence. Males participating in the study must have used a condom during the length of the study, and for at least 48 hours after discontinuing study medication. Protocol Amendment A.1AU included the required assessment for Austrian subjects to perform urine pregnancy tests every 4 weeks during the study.

Exclusion criteria

Exclusion Criteria:

  1. The subject permanently discontinued study drug during the previous study (TDE PH 202, TDE-PH-203, TDE PH 205, TDE-PH-301, TDE-PH-302, or TDE PH 308) due to treatment-related adverse events (AEs).
  2. The subject permanently discontinued study drug during the Treatment Phase of the previous study (TDE-PH-202, TDE-PH-203, TDE-PH-205, TDE-PH-301, TDE-PH-302, or TDE-PH-308) due to clinical worsening (as defined in those study protocols) and did not undergo premature termination assessments prior to discontinuing study drug, and/or did not complete all remaining study visits through the final scheduled visit.
  3. The subject prematurely discontinued study drug during the Treatment Phase of the previous study due to clinical worsening (as defined in those study protocols), completed premature termination assessments prior to discontinuing study drug, completed all remaining scheduled study visits AND received oral treprostinil during the Treatment Phase of the previous study (TDE PH-202, TDE-PH-203, TDE-PH-301, TDE-PH-302, or TDE PH-308). Subjects enrolled in Study TDE-PH-202 who were randomized into the individual maximum tolerated dose (iMTD) group who clinically worsened could not participate. Subjects who permanently discontinued study drug during the 12-week Treatment Phase due to treatment-related AEs were not eligible even if they completed all remaining scheduled study visits. Subjects who permanently discontinued study drug during the 12 week Treatment Phase and did not undergo premature termination assessments prior to discontinuing study drug and/or who did not complete all remaining study visits through the Week 12 visit were also not eligible.
  4. The subject developed any concurrent illness or condition during the conduct of the previous study, including but not restricted to: sleep apnea, chronic renal insufficiency, anemia, uncontrolled systemic hypertension, or left sided heart disease, unless their physician felt that entry into this study would not be detrimental to their overall health.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
894 participants (actual)

Study arms

  • Experimental
    Oral Treprostinil

    Subjects from previous studies TDE-PH-202 (NCT01104870), TDE-PH-203 (NCT01477333), and TDE-PH-205 (NCT01588405), TDE-PH-301 (NCT00325442), TDE-PH-302 (NCT00325403), or TDE PH-308 (NCT00887978). Subjects were instructed to take the appropriate amount of 0.125, 0.25, 0.5, 1, and/or 2.5 mg tablets based upon their prescribed dose. Investigators were instructed to increase the dose of oral treprostinil in the absence of dose limiting drug-related AEs to ensure each subject received the optimal clinical dose throughout the study

    Drug: Oral Treprostinil

Interventions

  • Oral sustained release tablet, twice or thrice daily. Open label study with active drug, no other intervention arms.

    Also known as: Treprostinil diethanolamine, treprostinil diolamine, UT-15C

06

What researchers measure

Primary outcomes

  1. Change in Exercise Capacity at Month 12

    Assess the effect of continued therapy with oral treprostinil on exercise capacity as assessed by the change from Baseline in 6-Minute Walk Test (6MWT) after 1 year of treatment. The 6MWT is the clinical standard for assessing subject functional status in the treatment of PAH and has been considered an objective measure of subject functional status by the American Thoracic Society. The distance a subject can walk in 6 minutes is recorded in meters.

    Time frame: From First Visit (Visit 1) to Month 12

07

Results

Posted May 10, 2021

Participant flow

Baseline values for demographic parameters were defined and collected in the same manner for subjects who received either placebo or oral treprostinil in the preceding studies. Note that Studies TDE-PH-202 (NCT01104870), TDE-PH-203 (NCT01477333), and TDE-PH-205 (NCT01588405) had an open-label design; therefore, all Baseline demographic parameters were based on values collected at the time of enrollment in the previous study.

Participant flow — Overall Study
MilestoneOral Treprostinil
Started894
Completed208
Not completed686
Withdrew: Death174
Withdrew: Progressive disease163
Withdrew: Adverse event172
Withdrew: Withdrawal by subject113
Withdrew: Lost to follow-up17
Withdrew: Protocol violation13
Withdrew: Pi decision8
Withdrew: Limited study drug effectiveness7
Withdrew: Non-compliance with study procedures7
Withdrew: Lung transplant5
Withdrew: Unable to tolerate study drug2
Withdrew: Use of excluded medication2
Withdrew: Patient self-discontinuation1
Withdrew: Pregnancy1
Withdrew: Surgery1

Outcome measures

PrimaryChange in Exercise Capacity at Month 12

Assess the effect of continued therapy with oral treprostinil on exercise capacity as assessed by the change from Baseline in 6-Minute Walk Test (6MWT) after 1 year of treatment. The 6MWT is the clinical standard for assessing subject functional status in the treatment of PAH and has been considered an objective measure of subject functional status by the American Thoracic Society. The distance a subject can walk in 6 minutes is recorded in meters.

Time frame:
From First Visit (Visit 1) to Month 12
Reported as:
Median · meters
Change in Exercise Capacity at Month 12
metersOral Treprostinil
Change in Exercise Capacity at Month 1222.0 (-345.0 to 282.0)

Adverse events

Collected over From the time of subject enrollment until exit from the study (up to 13 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Treprostinil174/894 (19.5%)547/894 (61.2%)890/894 (99.6%)
Most frequent serious events
Showing 10 of 401
Most frequent serious events
EventOral Treprostinil
Pulmonary HypertensionRespiratory, thoracic and mediastinal disorders129/894
Right ventricular failureCardiac disorders129/894
PneumoniaInfections and infestations63/894
DyspnoeaRespiratory, thoracic and mediastinal disorders41/894
Acute kidney injuryRenal and urinary disorders37/894
Cardiac failureCardiac disorders36/894
SyncopeNervous system disorders30/894
AnaemiaBlood and lymphatic system disorders28/894
Chest painGeneral disorders28/894
HypotensionVascular disorders23/894
Most frequent other events
Showing 10 of 59
Most frequent other events
EventOral Treprostinil
HeadacheNervous system disorders698/894
DiarrhoeaGastrointestinal disorders592/894
NauseaGastrointestinal disorders505/894
FlushingVascular disorders416/894
VomitingGastrointestinal disorders349/894
Pain in jawMusculoskeletal and connective tissue disorders313/894
Pain in extremityMusculoskeletal and connective tissue disorders255/894
DizzinessCardiac disorders248/894
Upper respiratory tract infectionInfections and infestations222/894
DyspnoeaRespiratory, thoracic and mediastinal disorders207/894

Baseline characteristics

All subjects enrolled in the study.

Age, Continuous
Age, Continuous(years)Oral Treprostinil
Mean47.7 (12 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Oral Treprostinil
Female696
Male198
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Oral Treprostinil
Hispanic or Latino83
Not Hispanic or Latino809
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Oral Treprostinil
American Indian or Alaska Native34
Asian219
Native Hawaiian or Other Pacific Islander2
Black or African American46
White589
More than one race0
Unknown or Not Reported4
Region of Enrollment
Region of Enrollment(participants)Oral Treprostinil
Puerto Rico1
United States436
United Kingdom27
Portugal1
India79
Spain6
Canada19
Austria7
Netherlands15
Sweden2
Belgium6
Ireland2
Poland16
Italy13
Mexico38
Israel22
Australia44
France22
Germany14
China124
PAH Etiology
PAH Etiology(Participants)Oral Treprostinil
Idiopathic Pulmonary Arterial Hypertension/ Heritable Pulmonary Arterial Hypertension608
Collagen Vascular Disease224
Other60
Missing2
World Health Organization (WHO) Functional Class
World Health Organization (WHO) Functional Class(Participants)Oral Treprostinil
I18
II298
III527
IV11
Missing40
08

Study locations

135 sites
  • The Kirklin Clinic
    Birmingham, Alabama 35233, United States
  • Arizona Pulmonary Specialists, Ltd.
    Phoenix, Arizona 85013, United States
  • Mayo Clinic Phoenix
    Phoenix, Arizona 85054, United States
  • St. Joseph's Hospital and Medical Center
    Phoenix, Arizona, United States
  • University Medical Center
    Tucson, Arizona 85724, United States
  • University of Arizona Clinical and Translational Science (CATS) Research Center
    Tucson, Arizona 85724, United States
  • University of California, San Francisco-Fresno
    Fresno, California 93701, United States
  • West Los Angeles VA Healthcare Center
    Los Angeles, California 90073, United States
  • David Geffen School of Medicine at UCLA
    Los Angeles, California 90095, United States
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • UCSD Medical Center
    San Diego, California 30322, United States
  • University of California San Francisco Medical Center
    San Francisco, California 94118, United States
  • Stanford University, Pulmonary and Critical Care Medicine
    Stanford, California 94305-5351, United States
  • Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • The Children's Hospital
    Aurora, Colorado 80045, United States
  • University of Colorado Health Science Center
    Aurora, Colorado 80045, United States
  • University of Florida College of Medicine Jacksonville
    Jacksonville, Florida 32209, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • The University of Chicago Hospitals
    Chicago, Illinois 60637, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Kentuckiana Pulmonary Associates
    Louisville, Kentucky 40202, United States
  • Alexandria Cardiology Clinic
    Alexandria, Louisiana 71301, United States
  • Maine Medical Center
    Portland, Maine 04102, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Johns Hopkins Outpatient Center
    Baltimore, Maryland 21287, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Brigham and Woman's Hospital
    Boston, Massachusetts 02114, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48103, United States
  • University of Minnesota Medical Center, Fairview
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110-1093, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198-5300, United States
  • Newark Beth Israel Medical Center
    Newark, New Jersey 07112, United States
  • Winthrop University Hospital
    Mineola, New York 11501, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Mary Parkes Center
    Rochester, New York 14643, United States
  • University of North Carolina Hospitals
    Chapel Hill, North Carolina 27599, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • The Carl and Ethyl Linder Center for Research and Education at the Christ Church
    Cincinnati, Ohio 45219, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267-0564, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • The University of Toledo Medical Center
    Toledo, Ohio 43614, United States
  • Legacy Pulmonary Clinic
    Portland, Oregon 97210, United States
  • Oregon Health and Sciences University
    Portland, Oregon 97239, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • UPMC Presbyterian Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-2650, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Texas Medical School
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • Intermountain Medical Center
    Murray, Utah 84157-7000, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Aurora Cardiovascular Services
    Milwaukee, Wisconsin 53215, United States
  • The Prince Charles Hospital
    Chermside West, 4032, Australia
  • Heart/Lung Transplant Unit - St. Vincent's Hospital
    Darlinghurst, 2010, Australia
  • The Alfred Hospital
    Melbourne, 3004, Australia
  • Royal Perth Hospital
    Perth, Australia
  • Medical University Graz
    Wein, Austria
  • Medizininische Universitaet Wien
    Wien, Austria
  • Universitaetsklinik für Innere Medizin Innsbruck
    Wien, Austria
  • Department of Cardiology Erasme University Hospital
    Brussels, Belgium
  • University Hospital Gasthuisberg
    Leuven, Belgium
  • Peter Lougheed Centre
    Calgary, Alberta T1Y 6J4, Canada
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Vancouver Coastal Health Authority Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
  • London Health Sciences Center Victoria Hospital
    Toronto, Ontario N6A 4G5, Canada
  • Sir Mortimer B. Davis Jewish General Hospital
    Montréal, Quebec H3T 1E2, Canada
  • Beijing Shijitan Hospital, Cadres Respiratory Department
    Beijing, China
  • Peking Union Medical College Hospital, Respiratory Medicine Department
    Beijing, China
  • Shanghai Pulmonary Hospital, Respiratory Medicine Department
    Shanghai, China
  • Service Chirurgie Thoracique, Hôpital Haut Levêque
    Pessac, Pessac Cedex 33604, France
  • PMAC, Clinique de Pneumologie
    Bernin, France
  • Centre d'Investigation Clinique Hôpital La Cavale Blanche - CHU Brest
    Brest, France
  • Hospital Antoine Beclere
    Clamart, France
  • Hospital Claude Huriez
    Lille Cedex, France
  • Hôpital Louis Pradel
    Lyon, France
  • CHU Arnaud de Villeneuve - Service maladies respiratoires
    Montpellier cedex 5, 34295, France
  • Service de Pneumologie Centre de Competence pour l'HTAP- Pole des Voies Respiratoires Hôpital Larrey
    Toulouse, France
  • Universitätsklinikum Dresden Abtl. Pneumologie
    Dresden, 01307, Germany
  • University Hospital Greifswald
    Greifswald, 17475, Germany
  • DRK Kliniken Berlin Köpenick
    Hamburg, Germany
  • Universitatsklinikum Hamburg Eppendorf
    Hamburg, Germany
  • Universitätsklinkium Köln Klinik III für Innere Medizin
    Hamburg, Germany
  • Zentrum für Lungenhochdruck Thoraxklinik am Universitätsklinikum Heidelberg
    Hamburg, Germany
  • Medizinische Hochschule Hannover (MHH)
    Hannover, Germany
  • Dept. of Internal Medicine III University Heidelberg
    Heidelberg, 69120, Germany
  • Care Institute of Medical Sciences
    Ahmedabad, Gujarat 380054, India
  • Narayana Hrudayalaya Hospitals
    Bangalore, Karnataka 560034, India
  • Asian Heart Institute & Research Centre Pvt. Ltd.
    Mumbai, Maharashtra 400012, India
  • Poona Hospital and Research Centre
    Pune, Maharashtra 411030, India
  • Life Care Institute of Medical Sciences & Research
    Ahmedabad, 380054, India

Showing the first 100 of 135 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2007 to primary completion in Feb 2020, 156 months.

Results were first posted in May 2021, 1 year 2 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 156 months is above that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2009
First posted
Dec 9, 2009
StartActual
Jan 16, 2007
Primary completionActual
Feb 12, 2020
CompletionActual
Feb 12, 2020
Results first posted
May 10, 2021
Last update
May 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01027949
Responsible party
Sponsor
First posted
Dec 9, 2009
Start date
Jan 16, 2007
Primary completion
Feb 12, 2020
Completion
Feb 12, 2020
Results posted
May 10, 2021
Last update
May 10, 2021
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion